Design and synthesis of new potent 5-HT7 receptor ligands as a candidate for the treatment of central nervous system diseases

Eur J Med Chem. 2022 Jan 5:227:113931. doi: 10.1016/j.ejmech.2021.113931. Epub 2021 Oct 21.

Abstract

Owing to their multifunctional pharmacological profiles (including dual 5-HT1A/5-HT7 action), arylpiperazine derivatives are widely used for treating central nervous system diseases including the depression or neuropathic pain. Herein we describe the design, synthesis and evaluation of biological activity of novel 5-HT7 ligands derived of 2,4,6-triamino-1,3,5-triazine. The studied compounds showed affinity and high selectively towards 5-HT7 receptor with the two most active compounds 34 (Ki = 61 nM), 22 (Ki = 109 nM) showing good metabolic stability and moderate affinity to CYP3A4 isoenzyme. Compound 22 had high hepatotoxicity at a concentration below 50 μM, while compound 34 showed low hepatotoxicity even at a concentration above 50 μM.

Keywords: 5-HT7; Aminotriazine; Medicinal chemistry; Microvave synthesis; lcap.

MeSH terms

  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Central Nervous System Diseases / drug therapy*
  • Central Nervous System Diseases / metabolism
  • Dose-Response Relationship, Drug
  • Drug Design*
  • Hep G2 Cells
  • Humans
  • Ligands
  • Models, Molecular
  • Molecular Structure
  • Receptors, Serotonin / metabolism*
  • Structure-Activity Relationship
  • Triazines / chemical synthesis
  • Triazines / chemistry
  • Triazines / pharmacology*

Substances

  • Ligands
  • Receptors, Serotonin
  • Triazines
  • serotonin 7 receptor
  • melamine